Azithromycin Use Rises as US Unscheduled Cesarean Infections Decline
Key Highlights
- Azithromycin use during cesarean births increased from 2.2% before the publication of trial evidence to 39.6% afterward.
- Postpartum infection rates following cesarean birth declined from 9.2% to 8%, while rates following vaginal birth increased.
- The adjusted difference-in-differences estimate for postpartum infection was −2.0 percentage points.
- The analysis assessed infections occurring within 6 weeks of delivery.
Adjunctive azithromycin use increased, and postpartum infection rates decreased among US patients undergoing unscheduled cesarean delivery after the publication of supporting trial evidence for azithromycin use in 2016, according to a study published in JAMA. The analysis examined how evidence translated into clinical practice across more than 1.66 million deliveries.
The investigators sought to quantify azithromycin adoption outside the original trial and describe subsequent infection trends. Although trial evidence had demonstrated reduced postpartum infection with adjunctive azithromycin at unscheduled cesarean delivery, its use beyond that setting had not previously been reported, according to the study.
Researchers used Epic Cosmos data for pregnant individuals who received prenatal care, labored, and delivered a liveborn singleton infant at 24–43 weeks’ gestation between 2013 and 2024. In the difference-in-differences design, cesarean births formed the treatment group and vaginal births served as controls.
Births from January 1, 2013, through September 28, 2016, were compared with those from January 1, 2017, through December 31, 2024. Primary outcomes were perioperative azithromycin administration and postpartum infection within 6 weeks. Patient-level linear regression generated adjusted difference-in-differences estimates.
Study Findings
The study included 202,234 cesarean births and 1,461,207 vaginal births. The mean maternal age was 29.3 years, and the median body mass index at delivery was 31.8. Azithromycin administration during cesarean births increased from 721 of 32,970 deliveries (2.2%) before the trial publication to 67,094 of 169,264 (39.6%) afterward. Corresponding use during vaginal births remained low, at 0.01% and 0.04%. The adjusted difference-in-differences estimate was an increase of 37.6 percentage points (95% CI, 33.1–42.2).
Postpartum infection following cesarean delivery declined from 3,048 of 32,970 births (9.2%) in the earlier period to 13,555 of 169,264 (8.0%) afterward. Over the same periods, infection following vaginal delivery increased from 2.0% to 2.7%. The adjusted difference-in-differences estimate was −2.0 percentage points (95% CI, −2.6 to −1.4). These results describe the study’s changes in clinical practice and infection rates across the 2 periods.
Clinical Implications
According to the authors, publication of the 2016 trial evidence was followed by increased azithromycin use and decreased postpartum infection rates among patients undergoing unscheduled cesarean delivery in the US.
Expert Commentary
“After publication of the trial evidence in 2016, azithromycin use for pregnant persons undergoing unscheduled cesarean delivery increased and postpartum infection rates decreased in the US,” the researchers concluded.
Reference
Freret TS, Litman E, Wen T, et al. Adoption of adjunctive azithromycin for unscheduled cesarean delivery and postpartum infections. JAMA. 2026;336(17):1539-1547. doi:10.1001/jama.2026.15010
